-
1.发明授权公开(公告)号：US09150542B2
公开(公告)日：2015-10-06
申请号：US14420249
申请日：2013-09-02
发明人： Sudhir Singh Sanwal , Anandam Vempali , Balaguru Murugesan , Swargam Sathyanarayana , Rajesh Kumar Thaper , Mohan Prasad
IPC分类号： C07D401/12
CPC分类号： C07D401/12
摘要： The present invention relates to a process for the preparation of crystalline Form I of methanesulfonate salt of dabigatran etexilate. (Formula (I)). The present invention does not require the isolation of the dabigatran etexilate intermediate.
摘要翻译： 本发明涉及一种制备达比加群酯甲磺酸盐晶型I的方法。 （式（I））。 本发明不需要分离达比加群酯。
-
2.发明申请PROCESS FOR THE PREPARATION OF CRYSTALLINE FORM I OF METHANESULFONATE SALT OF DABIGATRAN ETEXILATE 有权制备DABIGATRAN ETEXILATE的甲磺酸盐的晶体形式I的方法公开(公告)号：US20150197504A1
公开(公告)日：2015-07-16
申请号：US14420249
申请日：2013-09-02
发明人： Sudhir Singh Sanwal , Anandam Vempali , Balaguru Murugesan , Swargam Sathyanarayana , Rajesh Kumar Thaper , Mohan Prasad
IPC分类号： C07D401/12
CPC分类号： C07D401/12
摘要： The present invention relates to a process for the preparation of crystalline Form I of methanesulfonate salt of dabigatran etexilate. (Formula (I)). The present invention does not require the isolation of the dabigatran etexilate intermediate.
摘要翻译： 本发明涉及一种制备达比加群酯甲磺酸盐晶型I的方法。 （式（I））。 本发明不需要分离达比加群酯。
-
3.发明申请PROCESS FOR THE PREPARATION OF DABIGATRAN ETEXILATE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 审中-公开制备DABIGATRAN ETEXILATE或其药学上可接受的盐的方法公开(公告)号：US20150246899A1
公开(公告)日：2015-09-03
申请号：US14430303
申请日：2013-09-30
发明人： Anandam Vempali , Sudhir Singh Sanwal , Balaguru Murugesan , Swargam Sathyanarayana , Rajesh Kumar Thaper , Mohan Prasad
IPC分类号： C07D401/12 , C07C53/48 , C07C53/10 , C07D213/75 , C07C309/19
CPC分类号： C07D401/12 , C07C53/10 , C07C53/48 , C07C309/19 , C07D213/75
摘要： The present invention relates to a process for the preparation of dabigatran etexilate. The present invention also relates to trifluoroacetate salt of dabigatran etexilate and a process for its preparation. The present invention further relates to crystalline Form I and crystalline Form II of trifluoroacetate salt of dabigatran etexilate and processes for their preparation. The present invention further relates to a process for the preparation of pharmaceutically acceptable salts, including methanesulfonate salt, of dabigatran etexilate.
摘要翻译： 本发明涉及制备达比加群酯的方法。 本发明还涉及达比加群酯的三氟乙酸盐及其制备方法。 本发明还涉及达比加群酯的三氟乙酸盐的晶型I和结晶形式II及其制备方法。 本发明还涉及制备达比加群酯的药学上可接受的盐，包括甲磺酸盐的方法。
-
公开(公告)号：US20140336380A1
公开(公告)日：2014-11-13
申请号：US14360723
申请日：2012-11-21
IPC分类号： C07C213/02 , C07D487/18
CPC分类号： C07C213/02 , C07C213/08 , C07C231/02 , C07C303/02 , C07C303/32 , C07C309/40 , C07D487/18 , C07C217/60 , C07C233/18
摘要： The present invention provides a process for the preparation of agomelatine and its intermediate compounds. The invention also provides an intermediate compound of agomelatine represented by Formula (V).
摘要翻译： 本发明提供了一种制备agomelatine及其中间体化合物的方法。 本发明还提供由式（V）表示的阿魏酸的中间体化合物。
-
5.发明申请PROCESS FOR THE PREPARATION OF DABIGATRAN ETEXILATE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF 审中-公开制备DABIGATRAN ETEXILATE或其药学上可接受的盐的方法公开(公告)号：US20150225370A1
公开(公告)日：2015-08-13
申请号：US14430324
申请日：2013-09-30
发明人： Anandam Vempali , Sudhir Singh Sanwal , Balaguru Murugesan , Swargam Sathyanarayana , Rajesh Kumar Thaper , Mohan Prasad
IPC分类号： C07D401/12 , C07C303/32
CPC分类号： C07D401/12 , C07C303/32
摘要： The present invention provides hydrobromide salt of dabigatran etexilate of formula (IV) and its process for the preparation. The present invention further provides crystalline Form I and crystalline Form II of hydrobromide salt of dabigatran etexilate and processes for their preparation. The present invention further relates to a process for the preparation of pharmaceutically ac ceptable salts, including methanesulfonate salt, of dabigatran etexilate using hydrobromide salt of dabigatran etexilate of the present invention.
摘要翻译： 本发明提供式（IV）的达比加群酯的氢溴酸盐及其制备方法。 本发明还提供了达比加群酯的氢溴酸盐的晶型I和结晶形式II及其制备方法。 本发明还涉及使用本发明的达比加群酯的氢溴酸盐制备达比加群酯的药学上可接受的盐，包括甲磺酸盐的方法。
-
-
-
-
搜索结果
5 条记录 (耗时 0.014 秒)
